Advances in Pharmaceutical Innovations

Pharmaceutical innovations are currently guided by a patent system, the patent system protects the innovator of medicines for a period of time. The patent system does not currently stimulate innovation or pricing that provides access to medicine for those who need it the most. It provides for profitable innovation. As of 2014 about $140 Billion is spent on research and development of pharmaceuticals which produces 25-35 new drugs. Technology, which is transforming science, medicine, and research tools has increased the speed at which we can analyze data but we currently still must test the products which is a lengthy process. Differences in the performance of medical care may be due to variation in the introduction and circulation of pharmaceutical innovations.


In the present book, fifteen typical literatures about Pharmaceutical Innovations published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on biochemical pharmacology, clinical pharmacology, drug information, medicinal chemistry and pharmacognosy, molecular pharmacology, etc. We hope this book can demonstrate advances in pharmaceutical innovations as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry
  • Chapter 2
    Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact
  • Chapter 3
    Mapping supply dynamics in renewable feedstock enabled industries: A systems theory perspective on ‘green’ pharmaceuticals
  • Chapter 4
    Assessing Access to Medicines in Preferential Trade Agreements: From the Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership
  • Chapter 5
    3D Printing in Pharmaceutical and Medical Applications – Recent Achievements and Challenges
  • Chapter 6
    First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing
  • Chapter 7
    Dedicated innovation systems to support the transformation towards sustainability: creating income opportunities and employment in the knowledge-based digital bioeconomy
  • Chapter 8
    Innovations in biomedical nanoengineering: nanowell array biosensor
  • Chapter 9
    Medicines Information and the Regulation of the Promotion of Pharmaceuticals
  • Chapter 10
    Establishing Patient Centric Specifications for Drug Substance and Drug Product Impurities
  • Chapter 11
    Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions
  • Chapter 12
    On valuing biopharmaceutical product pipelines: an effectuation model and evidence
  • Chapter 13
    Raman spectroscopy as a process analytical technology for pharmaceutical manufacturing and bioprocessing
  • Chapter 14
    Inscrutable medicines and marginal markets: tackling substandard veterinary drugs in Nigeria
  • Chapter 15
    Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
Readership: Students, academics, teachers and other people attending or interested in pharmaceutical innovations
Economics Institute, Economics Institute, University of Hohenheim, Stuttgart, Germany

YoungTae Seo, Department of Computer Science, Queens College of the City University of New York, Flushing, USA

Dimitra Pappa, The Surrey Business School, University of Surrey, Guildford, Surrey, UK

Pete Kingsley, Centre of African Studies, The University of Edinburgh, Edinburgh, UK

Remco L. A. de Vrueh, Lygature, Utrecht, The Netherlands

Piergiuseppe Pusceddu, PhD Candidate, University of Tilburg, Tilburg, The Netherlands

and more...
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top